Reuters: Regulatory News: Sanofi's Genzyme recalls kidney transplant rejection drug

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Sanofi's Genzyme recalls kidney transplant rejection drug Aug 28th 2012, 12:57 Tue Aug 28, 2012 8:57am EDT Aug 28 (Reuters) - The U.S. health regulator said Sanofi's rare disease division, Genzyme, voluntarily recalled nine lots of its drug Thymoglobulin, which treats transplant rejection in kidney transplant patients. The recall was initiated on Aug. 2 when one lot of the drug failed a periodic stability test, a study to check the shelf life of a drug within specified conditions. "Genzyme has not identified any new safety risk to patients who have received Thymoglobulin from the implicated lot numbers, and there are no confirmed safety issues directly associated with the stability failure," U.S. Food and Drug Administration said in a recall notice on its website. The raw material used to produce Thymoglobulin was considered the cause of change in the shelf life of the drug. Additional lots, manufactured with comparable quality of the raw material, are also being recalled due to the potential risk of a stability failure. Shares of France-based Sanofi were trading slightly down at 65.31 euros on Tuesday.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions